Research Efforts in HER2+ Breast Cancer Pick Up Speed Despite COVID-19
April 9th 2021
Jane L. Meisel, MD, discusses sequencing questions, tucatinib combinations under exploration, and emerging strategies for use in the treatment of patients with HER2-positive breast cancer.